In an aspect, there is provided~~The present invention relates to~~ a compound of formula (I)



(I)

wherein

A represents –C≡C– or  ;

the ┈┈ bond represents a single bond or a double bond,

X represents carbon or nitrogen, and when X represents nitrogen then the ┈┈ bond represents a single bond;

Z_1 represents CH or N;

R^1 is hydrogen, C_{1-4}alkyl or halo;

R^2 is hydrogen, C_{1-4}alkyl or halo;

R^3 is hydrogen, C_{1-6}alkyl, hydroxy or halo;

R^4 is hydrogen; halo; C_{1-6}alkyl; C_{2-6}alkenyl; C_{2-6}alkynyl; C_{1-6}alkyloxy; C_{1-4}alkyloxycarbonyl; aminocarbonyl; mono- or di(C_{1-4}alkyl)-aminocarbonyl; aryl; aryloxy; arylcarbonyl; arylsulfonyl; heteroaryl; C_{1-6}alkyl substituted with cyano; C_{1-6}alkyl substituted with aryl or aryloxy; or C_{1-6}alkyl substituted with heteroaryl;

aryl is phenyl; phenyl substituted with one, two or three substituents each individually selected from halo, hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxy, polyhaloC_{1-4}alkyl, polyhaloC_{1-4}alkyloxy, cyano, nitro, and amino;

heteroaryl is furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiazolyl, indolyl, 2,3-dihydro-1H-indolyl, tetrahydrothiophenyl, or quinolinyl,

wherein each heteroaryl may be substituted with one or two substituents each independently selected from halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylcarbonyl, or phenyl;

or a pharmaceutically acceptable acid addition salt thereof.

In another aspect, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as defined herein.

In another aspect, there is provided a process for preparing a pharmaceutical composition as defined herein wherein a therapeutically active amount of a compound as defined herein is intimately mixed with a pharmaceutically acceptable carrier.

In another aspect, there is provided a compound of formula (I) as defined herein for use as a medicine.

In another aspect, there is provided a compound of formula (I) as defined herein for use in treating bacterial infections.

In another aspect, there is provided a process for preparing compounds of formula (I), as defined herein:

(i) by reacting an intermediate of formula (II) with an intermediate of formula (III),



(II) (III) (I)

(ii) for compounds of formula (I) in which A represents -C(R^2)=C(R^1)-, by reacting an intermediate of formula (V) with an intermediate of formula (VI),



(V) (VI) (I)

wherein X_{a1} represents a suitable leaving group and the other integers are as defined herein;

or; if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali.

As used in the foregoing definitions :

- halo is generic to fluoro, chloro, bromo and iodo;



wherein X_{a1} represents a suitable leaving group and the other integers are as defined in Claim 1;

or; if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali.

17. A compound of formula (I) as claimed in claim 1, selected from the group consisting of:

 (cis)	
Compound 1	Compound 2
 (cis)	
Compound 3	Compound 4
 (cis)	
Compound 5	Compound 6
 (cis)	
Compound 7	Compound 8

 (cis)	 (cis)
Compound 9	Compound 10
 (cis)	 (cis)
Compound 11	Compound 12
	
Compound 13	Compound 14
 (cis)	
Compound 15	Compound 16
	
Compound 17	Compound 18
 (cis)	
Compound 19	Compound 20
 (cis)	 (cis)
Compound 21	Compound 22

 (cis)	
Compound 23	Compound 24
 (cis)	 (cis)
Compound 25	Compound 26
 (cis)	 (cis)
Compound 27	Compound 28
 (cis)	
Compound 29	Compound 30
 (cis)	 (cis)
Compound 31	Compound 32
	 (cis)
Compound 33	Compound 34
	
Compound 35	Compound 36

 (cis)	 (cis)
Compound 37	Compound 38
 (cis)	
Compound 39	Compound 40
	 (cis)
Compound 41	Compound 42
 (cis)	
Compound 43	Compound 44
	 (cis)
Compound 45	Compound 46
 (cis)	 (cis)
Compound 47	Compound 48
 (cis)	 (cis)
Compound 49	Compound 50



(cis)

Compound 51



(cis)

Compound 52



(cis)

Compound 53



Compound 54



(cis)

Compound 55



Compound 56



(cis)

Compound 57



Compound 58



(cis)

Compound 59



(cis)

Compound 60



(cis)

Compound 61



(cis)

Compound 62



(cis)

Compound 63



(cis)

Compound 64

 (cis)	 (cis)
Compound 65	Compound 66
 (cis)	 (cis)
Compound 67	Compound 68
 (cis)	 (cis)
Compound 69	Compound 70
	 (cis)
Compound 71	Compound 72
 (cis)	
Compound 73	

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in claim 17.

19. A process for preparing a pharmaceutical composition as claimed in claim 18 wherein a therapeutically active amount of a compound as claimed in claim 17 is intimately mixed with a pharmaceutically acceptable carrier.

20. Compound of formula (I) as defined in claim 17 for use as a medicine.

21. A compound of formula (I) as defined in claim 17 for use in treating bacterial infections.

22. A compound as claimed in claim 21 wherein the bacterial infection is caused by a bacterium that expresses a FabI enzyme.